Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig

Trial StartspevatamigPositive

AI Analysis

Summary

Phanes Therapeutics announced the first patient has been dosed in a clinical study of spevatamig for colorectal cancer treatment. The company is a clinical-stage biotech focused on innovative immuno-oncology drug development.

Clinical Trial Data

Patients

Outcome Details

First patient dosed in clinical study

Importance:4/10

Sentiment:

0.30

immuno-oncologycolorectal cancerclinical-stagedrug development

Related Companies

$DFPH $TRAX

Read the original article

Published by PR Newswire Biotech on October 14, 2026 5:22 PM

Read Original